RESEARCH ARTICLE


Pilot Study of a New Adjustable Thermoplastic Mandibular Advancement Device for the Management of Obstructive Sleep Apnoea-Hypopnoea Syndrome: A Brief Research Letter



Mohammed El Ibrahimi1, *, Mounir Laabouri2
1 Centre des Maladies Respiratoires, 5 Bis, Rue Ibnou Babek, Quartier Racine, Maarif-Casablanca, Morocco
2 Home Air Maroc, 196 Av Mers Sultan, 20120 Casablanca, Morocco


Article Metrics

CrossRef Citations:
2
Total Statistics:

Full-Text HTML Views: 4063
Abstract HTML Views: 2209
PDF Downloads: 864
ePub Downloads: 738
Total Views/Downloads: 7874
Unique Statistics:

Full-Text HTML Views: 1876
Abstract HTML Views: 1207
PDF Downloads: 567
ePub Downloads: 489
Total Views/Downloads: 4139



Creative Commons License
© El Ibrahimi and Laabouri; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Centre des Maladies Respiratoires, 5 Bis, Rue Ibnou Babek, Quartier Racine, Maarif-Casablanca, Morocco; Tel: (+212) 522949246/522949347/522940838; Fax: (+212) 522949123; E-mail: afmapath@gmail.com


Abstract

Background:

Prefabricated adjustable thermoplastic mandibular advancement devices (PAT-MADs) are a practical short-term treatment for obstructive sleep apnoea-hypopnoea syndrome (OSAHS) in patients who have failed or refused continuous positive airway pressure (CPAP) therapy.

Objective:

To assess the effectiveness of a new professionally-fitted PAT-MAD in patients with OSAHS in Morocco.

Method:

Twenty-four adults with mild, moderate or severe OSAHS were fitted with the PAT-MAD (BluePro®; BlueSom, France). Respiratory parameters (apnoea-hypopnoea index (AHI), oxygen desaturation index (ODI)) and daytime sleepiness using the Epworth Sleepiness scale (ESS) were assessed before and after treatment. Adverse events were recorded.

Results:

Mean treatment duration was 106.3 ± 73.4 days. Mean AHI score decreased from 21.4 ± 7.4 to 9.3 ± 4.1 after treatment (p<0.0001) (mean reduction of 57.0 ± 12.3%). Mean ESS and ODI also decreased at EOS (from 10.4 ± 2.8 to 7.3 ± 2.3, mean reduction 30.3 ± 12.2%, p=0.0001; and 7.0 ± 6.9 to 4.7 ± 4.0, mean reduction 30.5 ± 25.0%, p=0.2, respectively). Treatment was considered to have been successful in 22 patients (91.7%) who had mild OSAHS or an AHI score of ≤5 at the end of the study. The device was well-tolerated.

Conclusion:

This new PAT-MAD appears to be effective at reducing respiratory parameters and improving daytime alertness in patients with OSAHS. Long term studies in a larger number of patients are warranted to assess the long-term efficacy, retention and side-effects of this device.

Keywords: Apnoea-hypopnoea index, Obstructive sleep apnoea-hypopnoea syndrome, Prefabricated adjustable thermoplastic mandibular advancement device, Respiratory parameters.